Related Experiment Videos

Role of complement in endotoxin/platelet-activating factor-induced lung injury

R Rabinovici1, C G Yeh, L M Hillegass

  • 1Department of Surgery, Jefferson Medical College, Philadelphia, PA 19107-5083.

Insights

Recombinant human soluble C receptor-1 protects against lung injury in a rodent model of adult respiratory distress syndrome by reducing edema and neutrophil infiltration. Complement factors play a key role in this condition.

Area of Science:

  • Immunology
  • Pulmonary Medicine
  • Complement System Research

Background:

  • C receptor-1 regulates C3 and C5-convertases.
  • Recombinant human soluble C receptor-1 (shC receptor-1) reduced infarct size in myocardial ischemia/reperfusion injury.
  • Adult respiratory distress syndrome (ARDS) involves complex inflammatory pathways.

Purpose of the Study:

  • To investigate the protective effect of shC receptor-1 on ARDS-induced pulmonary injury in a rodent model.
  • To elucidate the role of complement factors in LPS/platelet-activating factor-induced lung injury.

Main Methods:

  • ARDS model induced by Escherichia coli endotoxin (LPS) and platelet-activating factor (PAF).
  • Administration of shC receptor-1 (10 mg/kg or 1 mg/kg) or vehicle.
  • Assessment of pulmonary edema, myeloperoxidase activity, C3 and C5b-9 deposition, bronchoalveolar lavage fluid (BALF) cell counts and protein concentration, and serum TNF-alpha.
  • Complement depletion using cobra venom factor (CVF).

Main Results:

  • LPS/PAF induced microvascular lung injury with edema, increased BALF neutrophils and protein, and C3/C5b-9 deposition.
  • Pretreatment with shC receptor-1 (10 mg/kg) significantly prevented pulmonary edema, altered BALF cell counts and protein, and attenuated C3/C5b-9 deposition.
  • shC receptor-1 did not affect lung myeloperoxidase activity or serum TNF-alpha.
  • CVF-induced C depletion abolished pulmonary edema and elevated BALF leukocytes but did not impact myeloperoxidase activity or TNF-alpha.

Conclusions:

  • shC receptor-1 demonstrates a protective effect against LPS/PAF-induced ARDS-like pulmonary injury.
  • Complement factors, particularly C3 and C5b-9, are critically involved in the pathogenesis of ARDS.
  • shC receptor-1 may represent a potential therapeutic agent for ARDS.

Related Concept Videos